Thrombocytosis Interpreter — High Platelet Count, Reactive or ET?

Enter a platelet count with the context — an obvious reactive cause, whether it has persisted, driver-mutation results and age. It separates reactive thrombocytosis, which is most of them, from the clonal kind, flags the counts at which bleeding rather than clotting becomes the risk, and says when a high platelet count is a reason to look for cancer.

Last updated 21 Sep 2026

High platelet count

Platelets + context → reactive or clonal

Platelet count (× 10⁹/L)The same number as × 10³/µL. See the platelet count converter for other units.

Obvious reactive cause

Has the count stayed raised on repeat testing?

JAK2, CALR and MPL testing

Age

Reactive thrombocytosis from iron deficiency or bleeding is likelyExample

Platelets 620 × 10⁹/L, iron deficiency, single count, not tested, age 40 to 54

Where the causes came from in 732 patients (Griesshammer 1999)

87.7% + 12.3% = 100%. The four named reactive causes account for 89% of reactive cases; the rest had other causes. A hospital series, so it describes patients whose counts reached a laboratory, not the general population.
Group	Share
Reactive (secondary)	87.7% of all
— tissue damage (surgery, trauma)	42% of reactive
— infection	24% of reactive
— malignancy	13% of reactive
— chronic inflammation	10% of reactive
Primary (myeloproliferative)	12.3% of all

The platelet lines on this page

None of these lines separates reactive from clonal on its own.
Count (× 10⁹/L)	Why it matters	Source
Above 400	Common upper limit; cancer incidence 11.6% (men) and 6.2% (women) at one year in primary care	Bailey 2017
450 or more	Major criterion for essential thrombocythaemia — necessary, not sufficient	WHO 2022, ICC 2022
About 1,000–1,500	Where bleeding from acquired von Willebrand syndrome occurs in ET	StatPearls

The platelet count cannot tell you why it is high

Most raised platelet counts are reactive. In the largest referral series, 87.7% of 732 patients had a secondary cause — tissue damage, infection, malignancy, chronic inflammation, iron deficiency — and only 12.3% a myeloproliferative neoplasm (Griesshammer 1999). The count overlaps heavily between the two groups, so the number alone cannot separate them. Context does: a cause that is present, and a count that falls when it is treated.

The 450 × 10⁹/L line is widely misread. It is the first major criterion for essential thrombocythaemia in both 2022 classifications, which means ET cannot be diagnosed below it; it does not mean a count above it suggests ET. The diagnosis also needs a marrow with the typical megakaryocytes, exclusion of other myeloid neoplasms, and a JAK2, CALR or MPL mutation — or, in the one in ten adults without one, another clonal marker or the absence of a reactive cause.

Two numbers change management regardless of cause. Above about 1,000 × 10⁹/L in a myeloproliferative neoplasm, the risk turns from clotting to bleeding, through acquired von Willebrand syndrome. And an unexplained count above 400 in an adult is a cancer marker: in English primary care, 11.6% of men and 6.2% of women were diagnosed with cancer within a year, which is why NICE NG12 lists thrombocytosis among its referral features.

For platelet size, see the mean platelet volume interpreter; for a raised haemoglobin alongside, the polycythaemia interpreter.

Frequently asked questions

What is the most common cause of a high platelet count?

A reactive cause. In a series of 732 patients, 87.7% had secondary thrombocytosis, most often from tissue damage after surgery or trauma, infection, malignancy and chronic inflammation; iron deficiency and splenectomy are other common causes. Only 12.3% had a myeloproliferative neoplasm.

Is a platelet count over 450 essential thrombocythaemia?

Not by itself. A count of 450 × 10⁹/L or more is the first WHO and ICC criterion for essential thrombocythaemia, so ET cannot be diagnosed below it, but most people above it have reactive thrombocytosis. The diagnosis also needs a marrow, exclusion of other neoplasms, and usually a JAK2, CALR or MPL mutation.

Can a high platelet count be a sign of cancer?

Yes. In English primary care, adults with a platelet count above 400 × 10⁹/L had a one-year cancer incidence of 11.6% (men) and 6.2% (women), about three times that of people without. NICE NG12 includes thrombocytosis among the features that prompt a chest X-ray, endoscopy or pelvic ultrasound, depending on age and symptoms.

Can a very high platelet count cause bleeding?

Yes, in myeloproliferative neoplasms. At counts above roughly 1,000–1,500 × 10⁹/L, platelets bind and clear large von Willebrand factor multimers, causing acquired von Willebrand syndrome. Von Willebrand factor activity is checked before starting aspirin.

Related calculators

References

Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245(3):295–300. — 87.7% secondary (reactive), 12.3% primary; the commonest secondary causes tissue damage (42%), infection (24%), malignancy (13%) and chronic inflammation (10%); primary thrombocytosis associated with higher counts and more thromboembolism.
Bailey SER, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br J Gen Pract. 2017;67(659):e405–e413. — platelets above 400 × 10⁹/L; 1-year cancer incidence 11.6% in men and 6.2% in women with thrombocytosis, against 4.1% and 2.2% without.
National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE guideline NG12. — thrombocytosis in people aged 40 and over among the features prompting an urgent chest X-ray; raised platelets at 55 and over with nausea, vomiting, weight loss, reflux, dyspepsia or upper abdominal pain for non-urgent endoscopy; thrombocytosis with unexplained visible haematuria or vaginal discharge in women 55 and over for pelvic ultrasound (as tabulated by GPnotebook).
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. — polycythaemia vera: haemoglobin above 16.5 g/dL in men and 16.0 g/dL in women, or haematocrit above 49% and 48%, or red cell mass more than 25% above predicted; marrow panmyelosis; JAK2 V617F or exon 12; minor criterion subnormal serum erythropoietin; diagnosis with all three major, or the first two major plus the minor. Essential thrombocythaemia: platelets 450 × 10⁹/L or more. (Thresholds as tabulated side by side with the ICC by GIMEMA, 2024.)
Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. — the same haemoglobin, haematocrit, red cell mass and erythropoietin criteria for polycythaemia vera as the WHO 5th edition.
StatPearls. Essential Thrombocytosis. NCBI Bookshelf NBK539709, accessed September 2026. — WHO criteria including platelets 450 × 10⁹/L or more and a JAK2, CALR or MPL mutation; about 90% of adults carry one of the three; bleeding in ET often with platelets above 1,000–1,500 × 10⁹/L, through acquired von Willebrand syndrome.

Not medical advice. For healthcare professionals and education. Reference intervals vary by laboratory and assay — always use your own laboratory's. Never base a dose or a treatment decision on this page alone. Full disclaimer at calcengines.com/disclaimer/